Dr. Frédéric COIN

IGBMC, 1 rue Laurent Fries, Illkirch-Graffenstaden, 67400
Fix: 0388653449 Port:0778116917
fredr@igbmc.fr

Personal Situation

Date-of-birth: 06/10/1971
Nationality: French

Professional Situation

DR1, Group Leader INSERM 2017-2022
Team "*Genome Expression and Repair in Human Diseases*"
IGBMC, Illkirch-Graffenstaden

http://www.igbmc.fr/research/department/2/team/20/

Researcherid : F-5925-2013
ORCID : 0000-0002-5620-8519

h-index: 31
Sum of citations without self-citations 3460
Average citation/article: 55

Experience

Since 2021, Member of the Scientific Council, IGBMC
Since 2015, Director of Research 1, *Group Leader*, INSERM, IGBMC
2009-2014, Director of Research 2, *Principal Investigator*, INSERM, IGBMC
2005-2008, Research Assistant 1, INSERM, IGBMC
2001-2004, Research Assistant 2, INSERM, IGBMC

Education

PhD in Molecular Biology, University of Strasbourg, 2000

Scientific Activities

Courses

Plenary lecture Master 1 of Physiopathology and Master 1 of Molecular and Cellular Biology, University of Strasbourg

Scientific Panels

2005-2007 and **2010-2011**, Member of the commission SVSE2 of the French « Agence Nationale de la Recherche ».
2009-2014, Member of the national commission 2 of the ARC Fundation
2014, Member of the ATIP/Avenir commission LS1
2018-2021 Member of the commission "Ligue régionale Ile-de France".

Patents

F. Coin, Process for the detection and/or the measurement of damaged DNA and its application to the screening of cytotoxic agents acting on DNA. N° PCT/FR98/00339.
F.Coin, Use of spironolactone for treating cancer with platinium-based therapy. 2013. EP13306839.5

Organization of conferences

2005-2012, Member of the organization committee of the 3R Colloque "Réparation, Recombinaison, Réplication".
2013, Organization of the French-German "**Epigenetics and Genome Integrity** » October 7-10, 2013, Strasbourg-Illkirch, France.

Awards

2008, Prix Charles-Louis de Saulses de Freycinet, French Academy of Sciences

Five publications last 5 years

Berico P, Cigrang M, Braun C, Davidson G, Sandoz J, Legras S, Peyresaubes F, Gene Robles C, Egly J, Compe E, Davidson I, **Coin F*** (2021) CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma. **EMBO Reports** Sep 6;22(9):e51683. doi:10.15252/embr.202051683.
* Corresponding author and lead contact

Semer, M., Bidon, B. Larnicol, A., Caliskan G., Catez, P., Egly, JM., **Coin, F*.,** and Le May N. DNA repair complex licenses acetylation of H2A.Z.1 by KAT2A during transcription. **Nature Chemical Biology.** (2019).Oct;15(10):992-1000.
DOI: 10.1038/s41589-019-0354-y
* Corresponding author and lead contact

Sandoz J., Nagy Z., Catez Ph., Caliskan G., Gény S., Renaud JB, Concordet JP, Poterszman A., Tora L., Egly J-M, Le May N. and **Coin F***. (2019). Functional interplay between TFIIH and KAT2A (GCN5) regulates higher-order chromatin structure and class II gene expression. **Nature Communications.** Mar 20;10(1):1288. | DOI: 10.1038/s41467-019-09270-2.
* Corresponding author and lead contact

Bidon, b., Iltis, I., Semer, M., Nagy, Z., Larnicol, A., Cribier, A., Benkirane, M., **Coin, F***., Egly, J.M., and Le May, N., (2018). XPC is an RNA Polymerase II cofactor recruiting ATAC to promoters by interacting with E2F1. **Nature Communications**, 9:2610 | DOI: 10.1038/s41467-018-05010-0.
* Corresponding author

Alekseev, S., Nagy, Z., Sandoz, J., Weiss, A., Egly, J.M., Le May, N., and **Coin, F***. (2017). Transcription without XPB Establishes a Unified Helicase-Independent Mechanism of Promoter Opening in Eukaryotic Gene Expression. **Molecular Cell** *65*, 504-514 e504.

* Corresponding author and lead contact